ArticlePloS one2022
Use of oral polio vaccine and the incidence of COVID-19 in the world.
Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 23 citations in OpenAlex.
- Vaccination With Oral Polio Vaccine Reduces COVID-19 Incidence.Frontiers in immunology · 2022Trial
- Risk Adjustment in Medical Research: A Bird's Eye View.Journal of Korean medical science · 2024Review
- Toll-Like Receptors Agonists: First-Line Defense Tools in the Pandemic Preparedness Arsenal?Archives of Iranian medicine · 2024Article
- Article
- GPTZero Performance in Identifying Artificial Intelligence-Generated Medical Texts: A Preliminary Study.Journal of Korean medical science · 2023Article
- Prevalence and functional profile of SARS-CoV-2 T cells in asymptomatic Kenyan adults.The Journal of clinical investigation · 2023Article
- Article
- COVID-19 vaccines and a perspective on Africa.Trends in immunology · 2023Review
- Malaria and the incidence of COVID-19 in Africa: an ecological study.BMC infectious diseases · 2023Article
- Is it time to switch to a formulation other than the live attenuated poliovirus vaccine to prevent poliomyelitis?Frontiers in public health · 2023Review
- Oral Polio Vaccine to Mitigate the Risk of Illness and Mortality During the Coronavirus Disease 2019 Pandemic: A Cluster-Randomized Trial in Guinea-Bissau.Open forum infectious diseases · 2022Article
- One vaccine to counter many diseases? Modeling the economics of oral polio vaccine against child mortality and COVID-19.Frontiers in public health · 2022Article
- Ecosystems Determinants of Nutritional Adequacy Among the Indian Preschool Children.Journal of the Indian Institute of Science · 2022Review
- Use of Oral Polio Vaccine and the Global Incidence of Mother-to-Child Human Immunodeficiency Virus Transmission.Frontiers in public health · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSeveral live attenuated vaccines were shown to provide temporary protection against a variety of infectious diseases through stimulation of the host innate immune system.
objectiveTo test the hypothesis that countries using oral polio vaccine (OPV) have a lower cumulative number of cases diagnosed with COVID-19 per 100,000 population (CP100K) compared with those using only inactivated polio vaccine (IPV).
methodsIn an ecological study, the CP100K was compared between countries using OPV vs IPV. We used a random-effect meta-analysis technique to estimate the pooled mean for CP100K. We also used negative binomial regression with CP100K as the dependent variable and the human development index (HDI) and the type of vaccine used as independent variables.
resultsThe pooled estimated mean CP100K was 4970 (95% CI 4030 to 5900) cases per 100,000 population for countries using IPV, significantly (p<0.001) higher than that for countries using OPV-1580 (1190 to 1960). Countries with higher HDI prefer to use IPV; those with lower HDI commonly use OPV. Both HDI and the type of vaccine were independent predictors of CP100K. Use of OPV compared to IPV could independently decrease the CP100K by an average of 30% at the mean HDI of 0.72.
conclusionsCountries using OPV have a lower incidence of COVID-19 compared to those using IPV. This might suggest that OPV may either prevent SARS-CoV-2 infection at individual level or slow down the transmission at the community level.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.